Division of Critical Care, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta at Egleston, Atlanta, GA 30322, USA.
Intensive Care Med. 2011 Mar;37(3):518-24. doi: 10.1007/s00134-010-2090-3. Epub 2010 Dec 9.
Adult studies evaluating corticosteroids have found varied efficacy. One study showing mortality benefit utilized fludrocortisone (FLU) and hydrocortisone (HC) (Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862-871, 2002). Use of FLU in children has not been described. We developed a protocol using HC for systemic inflammatory response syndrome (SIRS) and shock with optional addition of FLU.
Addition of FLU to a HC-based steroid protocol is associated with decreased vasopressor duration without adverse effects in hypotensive children with SIRS.
Retrospective review of low-dose HC and FLU supplementation in children with SIRS and fluid refractory shock. Patients receiving FLU in addition to HC were compared with patients receiving HC alone.
Ninety-seven children with SIRS and shock received steroids. Sixty of 97 (62%) received FLU in addition to HC. Seventy-three children required dopamine (DA) infusion, and 56 received norepinephrine (NE). Overall mortality was 7/97 (7%), with 5/7 (71%) nonsurvivors receiving HC + FLU. Fifty of 97 (52%) children with SIRS met definition for sepsis. Septic children who received HC + FLU required NE for significantly shorter duration than those receiving HC alone (p = 0.011). Nineteen of 60 HC + FLU patients (32%) developed nonsymptomatic hypokalemia. Hypokalemia was significantly more common in HC + FLU patients compared with those receiving HC alone (p = 0.05).
Overall, addition of FLU in children with SIRS was not associated with decreased vasopressor duration or vasopressor score. However, HC + FLU was associated with shorter duration of NE support in the septic subgroup. Hypokalemia was a frequent adverse finding with HC + FLU (p = 0.05). Use of FLU should be considered in further studies evaluating the role of steroids in refractory pediatric septic shock.
成人研究评估皮质类固醇的疗效不一。一项研究表明皮质醇具有生存获益,该研究使用了氟氢可的松(FLU)和氢化可的松(HC)(小剂量氢化可的松和氟氢可的松治疗对感染性休克患者死亡率的影响。JAMA 288:862-871, 2002)。儿童中尚未描述 FLU 的应用。我们制定了一个使用 HC 治疗全身炎症反应综合征(SIRS)和休克的方案,可选择添加 FLU。
在伴有 SIRS 的低血压儿童中,在基于 HC 的类固醇方案中添加 FLU 可减少血管加压药的使用时间,而无不良反应。
回顾性分析 SIRS 和液体难治性休克患儿接受小剂量 HC 和 FLU 补充治疗的情况。比较接受 HC 加 FLU 治疗的患者与仅接受 HC 治疗的患者。
97 例 SIRS 和休克患儿接受了类固醇治疗。97 例患儿中有 60 例(62%)接受了 HC 加 FLU。73 例患儿需要多巴胺(DA)输注,56 例患儿需要去甲肾上腺素(NE)。总死亡率为 7/97(7%),5/7(71%)的死亡患儿接受了 HC + FLU 治疗。97 例 SIRS 患儿中有 50 例(52%)符合败血症的定义。接受 HC + FLU 的败血症患儿接受 NE 的时间明显短于单独接受 HC 的患儿(p = 0.011)。60 例接受 HC + FLU 的患儿中有 19 例(32%)发生无症状性低钾血症。与单独接受 HC 的患儿相比,接受 HC + FLU 的患儿低钾血症更常见(p = 0.05)。
总体而言,在 SIRS 患儿中添加 FLU 并未降低血管加压药的使用时间或血管加压药评分。然而,在败血症亚组中,HC + FLU 与 NE 支持时间较短有关。低钾血症是 HC + FLU 的常见不良发现(p = 0.05)。在评估皮质类固醇在难治性儿童感染性休克中的作用的进一步研究中,应考虑使用 FLU。